Scripscan:Jagsonpal Pharmaceuticals Ltd
cmp:14
Code:507789
Story:Jagsonpal Pharma is in the business of manufacturing capsules and bulk drugs for the pharmaceutical industry – with a focus on supplying solutions for lifestyle-related diseases (diabetes, blood pressure etc.)Jagsonpal Pharmaceuticals net profit rose 141.03% to Rs 0.94 crore in the quarter ended March 2012 as against Rs 0.39 crore during the previous quarter ended March 2011. Sales rose 30.13% to Rs 41.46 crore in the quarter ended March 2012 as against Rs 31.86 crore during the previous quarter ended March 2011. For the Audited full year,net profit rose 3.90% to Rs 7.46 crore in the year ended March 2012 as against Rs 7.18 crore during the previous year ended March 2011. Sales rose 9.66% to Rs 176.51 crore in the year ended March 2012 as against Rs 160.96 crore during the previous year ended March 2011.The company hasn’t really grown its revenues over the last five years but generated consistent operating profits – reporting about 13cr in operating profits on 176cr of revenues in the last financial year.It operated with modest debt of 29cr (as at 31st March, 201).The company is exposed to risks of price controls on the end products, high competition in an undifferentiated product category, falling behind on innovative and more effective drugs, and stringent supplier demands.
cmp:14
Code:507789
Story:Jagsonpal Pharma is in the business of manufacturing capsules and bulk drugs for the pharmaceutical industry – with a focus on supplying solutions for lifestyle-related diseases (diabetes, blood pressure etc.)Jagsonpal Pharmaceuticals net profit rose 141.03% to Rs 0.94 crore in the quarter ended March 2012 as against Rs 0.39 crore during the previous quarter ended March 2011. Sales rose 30.13% to Rs 41.46 crore in the quarter ended March 2012 as against Rs 31.86 crore during the previous quarter ended March 2011. For the Audited full year,net profit rose 3.90% to Rs 7.46 crore in the year ended March 2012 as against Rs 7.18 crore during the previous year ended March 2011. Sales rose 9.66% to Rs 176.51 crore in the year ended March 2012 as against Rs 160.96 crore during the previous year ended March 2011.The company hasn’t really grown its revenues over the last five years but generated consistent operating profits – reporting about 13cr in operating profits on 176cr of revenues in the last financial year.It operated with modest debt of 29cr (as at 31st March, 201).The company is exposed to risks of price controls on the end products, high competition in an undifferentiated product category, falling behind on innovative and more effective drugs, and stringent supplier demands.
